Filing Flows › Entrada Therapeutics (TRDA) › Q3 2026 › vs Q2 2026
Entrada Therapeutics (TRDA) Q3 2026 vs Q2 2026 (quarter over quarter)
Entrada Therapeutics's revenue rose $7K (+0.8%) from $898K in Q2 2026 to $905K in Q3 2026.
Entrada Therapeutics, Q3 2026: revenue $905K (-44% year over year), net loss $39.7M, operating cash flow −$30.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $905K | $898K | $7K | +0.8% |
| Other income, net | $2.0M | $2.2M | −$261K | -12% |
| Net loss | $39.7M | $42.8M | −$3.0M | -7% |
| Costs & expenses | $42.6M | $45.9M | −$3.3M | -7% |
| Operating costs | $42.6M | $45.9M | −$3.3M | -7% |
| Income tax | $27K | $35K | −$8K | -23% |
| Research & development | $32.4M | $35.4M | −$3.0M | -8% |
| General & admin | $10.2M | $10.5M | −$267K | -3% |
| Operating cash sources | $39.7M | $42.8M | −$3.0M | -7% |
| Depreciation | $700K | $800K | −$100K | -12% |
| Share-based compensation | $4.8M | $5.2M | −$372K | -7% |
| Working capital & other | $4.3M | $4.3M | −$50K | -1% |
| Cash used in operations | $30.0M | $32.5M | −$2.5M | -8% |
| Net loss absorbed | $39.7M | $42.8M | −$3.0M | -7% |
Questions
How much did Entrada Therapeutics's revenue grow quarter over quarter in Q3 2026?
Entrada Therapeutics's revenue rose $7K (+0.8%) from $898K in Q2 2026 to $905K in Q3 2026.